1	HIV-1 drug resistance in people on dolutegravir-based ART:		
2		Collaborative analysis of cohort studies	
3			
4 5 6 7	Tom Loosli <sup>1,2</sup> , Stefanie Hossmann <sup>3</sup> , Suzanne M. Ingle <sup>4</sup> , Hajra Okhai <sup>5</sup> , Katharina Kusejko <sup>1,2</sup> , Johannes Mouton <sup>6</sup> , Pantxika Bellecave <sup>7</sup> , Ard van Sighem <sup>8</sup> , Melanie Stecher <sup>9,10</sup> , Antonella d'Arminio Monforte <sup>11</sup> , M. John Gill <sup>12,13</sup> , Caroline A. Sabin <sup>5</sup> , Gary Maartens <sup>6</sup> , Huldrych F. Günthard <sup>1,2</sup> , Jonathan A C. Sterne <sup>4</sup> , Richard Lessells <sup>15,16,*</sup> , Matthias Egger <sup>3,4,16,*</sup> , Roger Kouyos <sup>1,2,*</sup>		
8	* Authors contributed equally		
9 10	1.	Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland	
11	2.	Institute of Medical Virology, University of Zurich, Zurich, Switzerland	
12	3.	Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland	
13	4.	Population Health Sciences, Bristol Medical School, University of Bristol, UK	
14	5.	Institute for Global Health, University College London, UK	
15	6.	Department of Medicine, University of Cape Town, Cape Town, South Africa	
16	7.	Virology laboratory, University Hospital Bordeaux, Bordeaux, France	
17	8.	Stichting hiv monitoring, Amsterdam, the Netherlands	
18	9.	German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Cologne, Germany	
19	10.	University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of	
20		Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf	
21	11.	. Italian Cohort Naive Antiretrovirals, (ICONA) L'Azienda Socio Sanitaria Territoriale (ASST)	
22		Santi Paolo e Carlo, Milano, Italy	
23	12.	Southern Alberta Clinic, Calgary, AB, Canada	
24	13.	Department of Medicine, University of Calgary, Calgary, AB, Canada	
25	14.	KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-	
26		Natal, Durban, South Africa	
27	15.	Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa	
28	16.	Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences,	
29		University of Cape Town, Cape Town, South Africa	
30			
31 32	Corres	pondence to: Prof Matthias Egger MD; matthias.egger@ispm.unibe.ch	
33	Word o	counts: Abstract 293 words, research in context 432 words, main text 3281 words, 2 tables, 4	

34 figures, 39 references, online appendix with 12 pages.

## 35 Summary

36

Background: The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for DTG resistance.

41 Methods: Eight cohorts from Canada, Europe, and South Africa contributed data on individuals with 42 genotypic resistance testing on DTG-based ART. Resistance levels were categorised using the 43 Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic 44 regression models.

45 **Results:** We included 750 people with genotypic resistance testing on DTG-based ART between 2013 46 and 2022. Most had HIV subtype B (N=444, 59.2%) and were treatment-experienced; 134 (17.9%) 47 were on DTG dual and 19 (2.5%) on DTG monotherapy. INSTI DRMs were detected in 100 ( $13\cdot3\%$ ) 48 individuals; 21 (2.8%) had more than one mutation. Most (N=713, 95.1%) were susceptible to DTG, 8 49 (1.1%) had potential-low, 5 (0.7%) low, 18 (2.4%) intermediate and 6 (0.8%) high-level DTG 50 resistance. The risk of DTG resistance was higher on DTG monotherapy (adjusted odds ratio (aOR) 51 37.25, 95% CI 11.17 to 124.2) and DTG lamivudine dual therapy (aOR 6.59, 95% Cl 1.70 to 25.55) 52 compared to combination ART, and higher in the presence of potential-low/low (aOR 4.62, 95% CI 53 1.24 to 17.2) or intermediate/high-level (aOR 7.01, 95% CI 2.52 to 19.48) nucleoside reverse 54 transcriptase inhibitors (NRTI) resistance. Viral load on DTG showed a trend towards increased DTG 55 resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of  $log_{10}$  area under the viral load 56 curve).

Interpretation: Among people experiencing virological failure on DTG-based ART, INSTI DRMs were
uncommon, and DTG resistance was rare. DTG monotherapy and NRTI resistance substantially
increased the risk for DTG resistance, which is of concern, notably in resource-limited settings.

60 **Funding:** US National Institutes of Health, Swiss National Science Foundation.

# 61 Research in context

### 62 Evidence before this study

63 We searched SCOPUS on 20 March 2023 for all publications from inception using the terms "dolutegravir" or "DTG", "resistant" or "resistance", and "HIV". The available evidence on resistance 64 65 evolution in people living with HIV (PLHIV) with virological failure on DTG-based ART is limited. Most 66 studies assessed the efficacy of DTG-based regimens in clinical studies and reported drug resistance 67 in individuals experiencing virological failure as a secondary objective or reported single or multiple 68 cases of patients developing resistance on DTG-based ART. Clinical trials such as the NADIA trial 69 showed a high degree of viral suppression even in people with NRTI resistance. Consequently, 70 previous analyses included only a small number of people experiencing failure on DTG; the SINGLE 71 trial with 39 people with virologic failure on DTG was the largest. The highest number of individuals 72 with DTG resistance was nine study participants in the NADIA trial. There is evidence that DTG 73 resistance in PLHIV on a DTG monotherapy may be more likely. Other studies suggest that HIV 74 subtype and mutations acquired during a first-generation INSTI-based regimen might affect the risk 75 of DTG resistance.

#### 76 Added value of this study

77 To our knowledge, this is the first study systematically investigating resistance in PLHIV experiencing 78 virologic failure on DTG-based ART using a multi-cohort collaboration design reflecting real-world 79 routine care. We collected genotypic resistance tests and clinical data from eight observational HIV 80 cohorts. This resulted in a large dataset of PLHIV experiencing virologic failure on a DTG regimen 81 (over 700 individuals). It allowed a robust assessment of drug resistance mutations and risk factors 82 for DTG resistance. Cross-resistance of first-generation INSTIs does not appear to explain the 83 mutation patterns in HIV-infected individuals who experience virological failure on DTG-based ART 84 regimens. PLHIV who received DTG monotherapy or DTG lamivudine dual therapy and those infected 85 with non-B subtypes were more likely to develop resistance. Resistance to NRTIs was a major risk 86 factor for DTG resistance, indicating that PLHIV receiving functional monotherapy are more likely to 87 develop DTG resistance.

#### 88 Implications of all the available evidence

HIV drug resistance is a significant threat to the sustainability of current and future antiretroviral therapy for combating the ongoing HIV pandemic. Our collaborative analysis shows that cases of DTG resistance are so far rare but not negligible. Given the global DTG roll-out, this might lead to increased frequencies and transmission of DTG resistance, particularly in PLHIV with resistance to

93 NRTIs. While the evidence regarding subtype differences is tentative, it indicates that non-B

subtypes, which are most relevant for the global roll-out of DTG, might be associated with an

95 increased risk of resistance.

# 96 Introduction

97 The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) was approved in 2013 in the United 98 States and shortly afterwards in the European Union to treat HIV infection. In 2019, the World 99 Health Organization (WHO) recommended DTG as the preferred drug for first-line and second-line 100 antiretroviral therapy (ART) in all populations, including pregnant women and those of childbearing 101 age. Since then, DTG-based ART was rolled out globally,<sup>1</sup> with about 100 countries including DTG in 102 their treatment guidelines by mid 2020.<sup>2</sup>

DTG has a high genetic barrier to resistance,<sup>3,4</sup> and relatively few people living with HIV (PLHIV) are 103 so far known to have developed resistance.<sup>5–7</sup> The mutations leading to DTG resistance may differ 104 105 between HIV subtypes. In INSTI-naïve PLHIV, DTG resistance is mainly associated with the R263K mutation,<sup>8,9</sup> which was observed in three cases of DTG resistance in the NADIA trial.<sup>10</sup> The N155H 106 mutation was present in two individuals with subtype A and C in the SAILING trial,<sup>11</sup> while the G118R 107 mutation appears to be facilitated by a natural polymorphism in subtype C.<sup>12</sup> In a recent study in 108 Ethiopia, the Q148H/K/R mutation was found to be less prevalent in subtype C.<sup>13</sup> Pre-existing 109 mutations, such as those acquired during a first-generation INSTI regimen, may directly confer 110 resistance to DTG or affect the accumulation of additional mutations.<sup>14,15</sup> 111

The risk factors and the mutational patterns that confer resistance to DTG in vivo are less well established than for older antiretroviral drugs.<sup>16</sup> The widespread use of DTG in resource-limited settings, where ART regimens are highly standardised, drugs are recycled, access to adherence support, viral load and resistance testing is limited, may facilitate the emergence of resistance. We combined data from European, North American, and South African cohorts to identify risk factors for DTG resistance and to examine the patterns of resistance mutations across different HIV subtypes.

## 118 Methods

## 119 Data sources

120 We pooled data from eight HIV cohorts, including six European, one Canadian, and one South African cohort: the AIDS Therapy Evaluation in the Netherlands cohort (ATHENA),<sup>17</sup> the Agence 121 Nationale de la Recherche sur le SIDA et les hépatites virales (ANRS CO3), Aquitaine Cohort,<sup>18</sup> 122 the Italian Cohort of Antiretroviral-Naïve Patients (ICONA),<sup>19</sup> the Köln/Bonn Cohort (CBC), 123 Germany,<sup>20</sup> the UK Collaborative HIV Cohort (UK CHIC) Study (and linked UK HIV Drug Resistance 124 Database (UKHDRD)),<sup>21</sup> the Swiss HIV Cohort Study (SHCS),<sup>22</sup> the South Alberta Clinic Cohort 125 (SAC), Canada,<sup>23</sup> and the South African Aid for AIDS (AfA) cohort.<sup>24</sup> The European and North-126 American cohorts (apart from UK CHIC) participate in the ART Cohort Collaboration (ART-CC)<sup>25</sup> and 127

AfA in the International epidemiology Databases to Evaluate AIDS (IEDEA).<sup>26</sup> The clinical data were provided by the data centres of the two cohort collaborations, and the genotypic data by the cohorts.

#### 131 Inclusion criteria

Participants who underwent genotypic resistance testing from plasma HIV-1 RNA covering the integrase gene between two weeks after starting and up to two months after stopping any DTGbased regimen were eligible. In the case of multiple genotypic resistance tests, the latest was considered. Participants with unknown dates of initiation of DTG-based ART were excluded. The analysis of risk factors for DTG resistance was restricted to individuals with at least one year of follow-up.

### 138 HIV drug resistance

139 We defined two HIV drug resistance outcomes: the level of resistance to DTG and the presence of 140 known drug resistance mutations (DRMs). The Stanford HIV Database version 9.0 and the Stanford HIVdb algorithm<sup>27</sup> were used to categorise drug resistance levels as susceptible (score below 10), 141 142 potential low (10-14), low (15-29), intermediate (30-59) or high (>60). The same approach was used 143 to assess resistance to all other antiretroviral drugs, whereby drug resistance to tenofovir 144 alafenamide (not covered by the Stanford algorithm) was considered equal to tenofovir resistance. 145 Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was calculated as the median 146 of the scores for efavirenz, etravirine, nevirapine, and rilpivirine. Resistance to nucleoside reverse 147 transcriptase inbibitors (NRTIs) was calculated as the median of abacavir, zidovudine, 148 emtricitabine/lamivudine, and tenofovir scores (see sensitivity analyses for alternative definitions).

#### 149 HIV subtyping

150 We determined HIV subtypes from the integrase gene using COMET (COntext-based Modeling for Expeditious Typing)<sup>28</sup> and REGA.<sup>29</sup> If REGA and COMET output differed, the subtype with higher 151 152 support was assigned. As nucleotide sequecnes were not available for AfA, we used subtype 153 information as provided by the cohort based on reverse transcriptase (RT) and protease. For 154 Aguitaine, information on subtype was used where available, and otherwise considered as unknown. 155 The Aquitaine subtypes were characterised locally using Blast analysis on Smartgene HIV module on 156 two genes at least. In the analysis, we grouped HIV subtypes other than the four most common 157 subtypes (B, C, A, G) as other (subtypes F, AD, AE, D, 06 CPX, 18 CPX, unknown). The appendix (p 1) 158 provides further details.

159

#### 160

#### 161 **Definitions**

162 Individuals who were prescribed raltegravir or elvitegravir before starting the DTG-based regimen 163 were considered exposed to first-generation INSTIs. Viral load testing frequency was calculated for 164 individuals with more than one year of follow-up before the Genotypic Resistance Test (GRT). We 165 quantified HIV viral load as the area under the curve (AUC) of the log<sub>10</sub>-transformed viral load 166 measurements from DTG initiation to the GRT sample date. To account for differences in detection 167 limits, we set any viral load measurement below 50 to 0 copies/ml. For individuals who initiated ART 168 with the DTG-based regimen, we excluded high viral loads at ART initiation by setting measurements 169 within the first 180 days from the first HIV RNA measurement to 0. Time on DTG-based ART was 170 calculated in years from DTG initiation to GRT. The ART regimen at GRT was considered the regimen 171 an individual was taking 14 days before the test. If available, GRT results from earlier time points 172 were used to assess prior NRTI resistance.

#### 173 Statistical analysis

174 We used descriptive statistics to present the characteristics of the study population and the different 175 INSTI drug-resistance mutations. A negative binomial generalised linear model, adjusting for HIV 176 subtype, exposure to first-generation INSTIs, and sex, was used to analyse the number of major and 177 accessory INSTI drug-resistance mutations. We used ordinal logistic regression to identify risk factors 178 for developing resistance, including cohort as a random effect. We considered variables based on 179 availability and clinical relevance. We included sex, age at initiation and time on the DTG-based 180 regimen, HIV subtype, type of ART (combination ART based on three drugs or more, DTG lamivudine 181 dual therapy, other lamivudine dualtherapy, or monotherapy), exposure to first-generation INSTIs, 182 HIV viral load, viral load testing frequency, and resistance to NRTIs. The missing data was included as 183 a separate category if the sequencing did not cover the RT. All analyses were performed in R, version 184 4.0.5.

#### 185 Sensitivity analyses

We performed several sensitivity analyses. First, we replaced the NRTI resistance variable with the presence or absence of the M184V/I mutation (sensitivity analysis S1). Further, we performed logistic regression using the same covariables as in the main risk factor analysis, using susceptible versus any DTG resistance as the outcome (S2). We repeated the risk factor analyses excluding study participants where RT was not sequenced (S3). Given the widespread use of tenofovir-lamivudinedolutegravir (TLD), we restricted the analysis of NRTIs to tenofovir and lamivudine and used the

- 192 higher resistance level of the two to quantify NRTI resistance (S4). In the subset of people on a DTG +
- 193 2 NRTI regimen, we calculated NRTI resistance specific to the two NRTIs used in each participant
- 194 (S5). The main analysis could not assess whether NRTI and NNRTI resistance mutations pre-existed
- or were acquired on DTG. Sensitivity analysis S6 restricted the study population to participants with
- available GRTs before experiencing virological failure on the DTG-containing regimen.

#### 197 Role of the funding source

- 198 The funders of the study did not participate in the study design, data collection, data analysis, data 199 interpretation, and writing of the report. The corresponding author had full access to the data of this
- study and had the final responsibility for the decision to submit for publication.

#### 201 **Results**

A total of 750 people met the eligibility criteria and were included in the analysis of mutations conferring resistance to DTG; 677 (90.3%) had more than one year of follow-up since starting the DTG-based regimen and were included in the analysis of risk factors for DTG resistance.

#### 205 Characteristics of the study population

206 The study participants included in the two analyses were similar (**Table 1**): most participants were 207 men living with HIV subtype B who were on combination ART with three or more antiretroviral 208 drugs. The median year of starting DTG was 2016. People were on DTG for a median of 16 and 1.7 209 years, and the median AUC of log10 viral load (copies/mL) accumulated during this period was 210 around 3. The first GRT was performed in May 2013, and the last in January 2022. About a third of 211 participants had previously been exposed to first-generation INSTIs. A total of 193 people did not 212 have a CD4 measurement within a year of the GRT, 25 did not have any recorded HIV RNA 213 measurements before the GRT, and in 74 people sequencing did not cover RT. The appendix (p 1) 214 provides further details on the ART regimens.

## 215 INSTI mutations and DTG resistance

At least one major or accessory INSTI DRM was found in 100 (13.3%) of the 750 study participants;

21 (2.8%) had more than one mutation. Most (713; 95.1%) study participants were fully susceptible

- to DTG, with potential low, low, intermediate, and high levels of DTG resistance being observed in 8
- 219 (1.1%), 5 (0.7%), 18 (2.4%) and 6 (0.8%), respectively (**Figure 1**). The INSTI resistance mutations
- observed in all enrolled people with a DTG resistance score > 0 are shown in the appendix (p 2).
- The most common major INSTI DRM was R263K (N=11), which only once occurred with another major INSTI DRM (appendix p 2). Other common major mutations included the G140 (N = 10), N155

223 (N = 9), Q148 (N = 8), and the E138 mutation (N = 7). The G118R mutation, which has the strongest 224 impact on susceptibility to DTG, was only observed three times. Among accessory DRMs, E157 (N = 225 25) and T97 (N = 20) were the most common. The distribution of INSTI resistance mutations was 226 similar in people previously exposed to first-generation INSTIs and those not exposed (Figure 2). 227 There was no statistically significant association of specific DRMs with first-generation INSTI 228 experience. For HIV subtype, we found a significant association for the accessory INSTI DRM T97 (see 229 appendix p 3). This DRM occurred in 6 of 56 (10.7%) people with HIV subtype A, 4 of 42 (9.5%) 230 people with subtype G, 7 of 444 (1.6%) people with subtype B, and 0 of 71 people with HIV subtype 231 C.

The results from the negative binomial model of the number of mutations showed little evidence of a difference between HIV subtypes. The number of INSTI DRMs was higher in first-generation INSTIexposed people (adjusted RR 1.59, 95% CI 1.03 to 2.48) (**Figure 3**). This association became even stronger when considering the number of major INSTI DRMs (adjusted RR 2.60, 95% CI 1.30 to 5.31) (see appendix p 4 for further details).

The prevalence of resistance mutations (low, intermediate or high) to NRTIs and NNRTIs was substantially higher in the presence of DTG resistance (Table 2). Among GRTs with coverage of the RT, the prevalence of at least low level NRTI resistance was 10.1% overall (66 of 654) but 31.8% (7 of 22) among those with DTG resistance. The corresponding figures for NNRTI resistance were 12.8% (84 of 654) and 50% (11 of 22).

## 242 Risk factors for DTG resistance

243 The risk of DTG resistance was higher on DTG monotherapy compared to combination ART with >3 244 drugs (adjusted odds ratio [aOR] 37.25, 95% CI 11.17 to 124.2) and for DTG lamivudine dual regimen 245 (aOR 6.59, 95% CI 1.70 to 25.55) (Figure 4). The risk of resistance was also increased in the presence 246 of a potential low/low level of NRTI resistance (aOR 4.62, 95% CI 1.24 to 17.2) or intermediate/high 247 level (aOR 7.01, 95% CI 2.52 to 19.48), compared to no NRTI resistance. Non-B HIV subtypes tended 248 towards higher resistance levels, mainly driven by subtype A (aOR 3.27, 95% CI 249 0.90 to 11.87) (appendix p 5). There was a trend for an association of viral load with DTG 250 resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of the log<sub>10</sub> virus load area under 251 the curve).

## 252 Sensitivity analyses

The results of the risk factor analyses were similar when replacing the NRTI resistance variable with the M184V/I mutation (sensitivity analysis S1, appendix p 7) or when analysing susceptible versus

255 any DTG resistance as the outcome in a logistic regression (S2, appendix p 8). The exclusion of 64 256 individuals with missing RT sequences allowed the inclusion of both NRTI and NNRTI resistance in 257 the model. The results for NRTI resistance were similar, and intermediate/high-level NNRTI 258 resistance was also associated with DTG resistance (adjusted OR 4.07, 95% CI 1.07 - 15.5) (S3, 259 appendix p 9). The analysis restricted to lamivudine and tenofovir (S4, appendix p 10) confirmed that 260 DTG resistance was associated with potential low/low and intermediate/high-level resistance to 261 these NRTI drugs. Similarly, when restricting the analysis to people on a DTG regimen with two NRTI 262 backbones, we found similar results for the specific NRTIs (S5, appendix p 11). Finally, in the last 263 sensitivity analysis (S6) we used data on pre-existing NRTI resistance and found that DTG resistance 264 was associated with prior intermediate/high NRTI resistance (appendix p 12).

## 265 **Discussion**

266 In this collaborative analysis of eight large cohort studies, we identified INSTI DRMs in 100 of 750 267 (13.3%) PLHIV who experienced virologic failure on DTG-based ART, and resistance to DTG according 268 to the Stanford algorithm was present in 37 (4.9%) individuals. DTG resistance was associated with 269 DTG monotherapy, lamivudine DTG dual therapy, resistance to RT inhibitors, non-B subtype, and HIV 270 viral replication but not with previous first-generation INSTI exposure. A wide range of INSTI DRMs 271 was present. The polymorphic accessory INSTI DRM T97A was detected more frequently in subtypes A and G (compared to subtypes B and C), consistent with previously reported data.<sup>30</sup> The major INSTI 272 273 DRMs at positions 140 and 148 were detected in 5 out of 6 people with high-level DTG resistance, all 274 of whom were first-generation INSTI experienced.

275 DTG monotherapy, DTG lamivudine dual therapy and resistance to the NRTI backbone were most 276 strongly associated with DTG resistance in our study. The complete sequence analysis, which 277 allowed us to distinguish between NRTI and NNRTI resistance, suggests that the association may be 278 mediated via NRTI resistance. It was robust when considering only 3TC and TDF resistance in a 279 sensitivity analysis. As the main analysis was cross-sectional, it did not allow the determination of 280 the timing of NRTI resistance relative to DTG resistance. However, an additional analysis in people 281 with prior resistance tests suggests that NRTI resistance may often have predated DTG resistance. 282 These results indicate that resistance to NRTI backbone drugs from previous regimens may have 283 promoted the emergence of DTG resistance. However, its also possible that prior NRTI resistance 284 reflects adherence issues, which may facilitate the emergence of DTG resistance.

The strong associations of DTG resistance with DTG monotherapy and NRTI resistance are consistent with previous findings,<sup>10,31,32</sup> but appear to contradict the results from the NADIA trial, which found no evidence that the efficacy of DTG-based ART is affected by resistance to the NRTI backbone.<sup>10</sup>

However, it should be noted that the NADIA trial examined the risk of virological failure in 235 PLHIV randomised to DTG, resulting in a small number of treatment failures (n=24), while our study focused on the risk of resistance among people who experienced virological failure. Thus, for DTGbased regimens, NRTI resistance may not substantially affect the risk of treatment failure but still increase the risk of resistance in case of failure. Research on other drug classes<sup>33</sup> has shown that drug regimens with high and low genetic barriers can have similar failure rates but different probabilities of acquiring resistance.

295 Our study contributes new information on DTG resistance in PLHIV receiving different DTG-based 296 ART regimens by examining risk factors for DTG resistance in real-world cohort data from different 297 settings. The cohort collaboration resulted in a large dataset of GRT results in people who 298 experienced virological failure on DTG. Our results are central to informing HIV treatment and 299 monitoring policies in the context of the continued expansion of DTG-based treatment regimens. 300 The pooling of data from diverse routine clinical cohorts also has limitations. The data come from 301 individuals receiving any DTG-based regimen in a wide range of different clinical care settings. We 302 only included people who experienced virological failure and had a GRT, but policies and practices 303 regarding when and for whom GRT is done likely differed between cohorts. In our regression 304 models, we accounted for this heterogeneity between cohorts by including cohort as a random 305 effect, but confounding by cohort may still have affected our results. Further, the personalised 306 approach to ART and HIV care in the European settings will not be generalisable to other settings, 307 particularly low- and middle-income countries.

308 A further limitation of our study is the dominance of HIV subtype B, which was expected considering 309 that our study population is comprised mainly of PLHIV from European countries, where subtype B 310 predominates. More data from people with non-B subtypes are needed, and such a study is ongoing within the framework of the International epidemiology Databases to Evaluate AIDS (IeDEA).<sup>26</sup> In this 311 312 study, individuals experiencing failure on DTG-based ART are prospectively enrolled in around forty 313 sites across sub-Saharan Africa, South America, and Asia. Furthermore, the WHO plans to launch sentinel surveys of acquired HIV resistance to DTG among people receiving DTG-based ART.<sup>34</sup> We 314 315 could not assess adherence or drug interactions with rifampicin, which may influence the emergence of DTG resistance.<sup>35</sup> Adherence and rifampicin use were not recorded consistently and comparably 316 317 in the participating cohorts. In our study population, the DTG-based regimens were too 318 heterogenous to allow investigating DTG resistance outcomes of specific regimens and treatment 319 histories. Lastly, there is growing evidence that mutations outside integrase may confer DTG resistance<sup>36-38</sup>. Our study was based on pol sequences, which did not allow us to investigate these 320 321 mutations.

322 The associations we found with DTG resistance, resistance to NRTI backbone drugs, HIV-1 subtype, 323 and unsuppressed virus load have important implications for ensuring the long-term sustainability of 324 ART. While INSTI resistance was rare in our population; it is still a concern. Firstly, the duration of 325 DTG therapy and the duration of viraemia whilst receiving DTG was relatively short in our 326 population: the median time on DTG was less than 2 years and drug resistance might emerge more 327 frequently in settings where individuals remain viraemic for a longer time on DTG regimens. This 328 could happen in resource-limited settings where guidelines recommend not switching from DTG-329 based therapy unless multiple viral loads >1000 copies/mL have been documented and where delays in regimen switching are common.<sup>39</sup> Secondly, the strong association of DTG resistance with NRTI 330 331 resistance suggests that the risk of resistance might be higher in people with previous failure on 332 NNRTI-based first-line therapy, among whom the prevalence of NRTI resistance is much higher than 333 in our study population. The WHO guidelines recommend DTG in 1st-, 2nd- and 3rd-line ART. This 334 multiplicity of roles combined with the recycling of drugs and limited access to viral load and drug resistance testing will facilitate the emergence of DTG resistance. Finally, even a relatively low level 335 336 of acquired DTG resistance in the millions of people receiving DTG-based ART could lead to rising 337 levels of transmitted INSTI resistance, which could affect both treatment and prevention

In conclusion, our study underlines the importance of routine viral load monitoring and resistance
 testing, especially in treatment-experienced people, to prevent resistance both at the individual

patient and the population level and thereby ensure the long-term sustainability of ART.

# 341 Figures & tables

342 Table 1: Demographics and clinical characteristics in the study population. People with virological

343 failure on DTG-based ART with available genotypic resistance tests from eight observational HIV

344 cohorts were included in the study. Study participants where clinical data was available for at least

one year were considered for analysing risk factors for DTG resistance.

conferring mutations         for DTG resistance           Nale         (N=750)         (N=677)           Male         522 (69·6%)         463 (68·4%)           Female         228 (30·4%)         214 (31·6%)           Age at DTG Initiation (years)         46 [38 – 54]         47 [38 – 54]           HIV Subtype             B         444 (59·2%)         403 (59·5%)           C         71 (9·5%)         53 (7·8%)           C         71 (9·5%)         65 (9·6%)           G         42 (5·6%)         39 (5·8%)           Other*         137 (18·3%)         117 (17·3%)	'S	
(N=750)         (N=677)           Sex            Male         522 (69.6%)         463 (68.4%)           Female         228 (30.4%)         214 (31.6%)           Age at DTG Initiation (years)         46 [38 – 54]         47 [38 – 54]           HIV Subtype             B         444 (59.2%)         403 (59.5%)           C         56 (7.5%)         53 (7.8%)           C         71 (9.5%)         65 (9.6%)           G         42 (5.6%)         39 (5.8%)           Other*         137 (18.3%)         117 (17.3%)	for DTG resistance	
Sex           Male         522 (69.6%)         463 (68.4%)           Female         228 (30.4%)         214 (31.6%)           Age at DTG Initiation (years)         46 [38 – 54]         47 [38 – 54]           HIV Subtype         444 (59.2%)         403 (59.5%)           A         56 (7.5%)         53 (7.8%)           C         71 (9.5%)         65 (9.6%)           G         42 (5.6%)         39 (5.8%)           Other*         137 (18.3%)         117 (17.3%)		
Male       522 (69.6%)       463 (68.4%)         Female       228 (30.4%)       214 (31.6%)         Age at DTG Initiation (years)       46 [38 – 54]       47 [38 – 54]         HIV Subtype       444 (59.2%)       403 (59.5%)         A       56 (7.5%)       53 (7.8%)         C       71 (9.5%)       65 (9.6%)         G       42 (5.6%)       39 (5.8%)         Other*       137 (18.3%)       117 (17.3%)		
Female         228 (30.4%)         214 (31.6%)           Age at DTG Initiation (years)         46 [38 – 54]         47 [38 – 54]           HIV Subtype         444 (59.2%)         403 (59.5%)           A         56 (7.5%)         53 (7.8%)           C         71 (9.5%)         65 (9.6%)           G         42 (5.6%)         39 (5.8%)           Other*         137 (18.3%)         117 (17.3%)		
Age at DTG Initiation (years)       46 [38 – 54]       47 [38 – 54]         HIV Subtype       444 (59·2%)       403 (59·5%)         A       56 (7·5%)       53 (7·8%)         C       71 (9·5%)       65 (9·6%)         G       42 (5·6%)       39 (5·8%)         Other*       137 (18·3%)       117 (17·3%)		
HIV Subtype         B       444 (59·2%)       403 (59·5%)         A       56 (7·5%)       53 (7·8%)         C       71 (9·5%)       65 (9·6%)         G       42 (5·6%)       39 (5·8%)         Other*       137 (18·3%)       117 (17·3%)		
B       444 (59·2%)       403 (59·5%)         A       56 (7·5%)       53 (7·8%)         C       71 (9·5%)       65 (9·6%)         G       42 (5·6%)       39 (5·8%)         Other*       137 (18·3%)       117 (17·3%)		
A       56 (7.5%)       53 (7.8%)         C       71 (9.5%)       65 (9.6%)         G       42 (5.6%)       39 (5.8%)         Other*       137 (18.3%)       117 (17.3%)		
C       71 (9·5%)       65 (9·6%)         G       42 (5·6%)       39 (5·8%)         Other*       137 (18·3%)       117 (17·3%)         ART regimen at resistance genotyping		
G       42 (5.6%)       39 (5.8%)         Other*       137 (18.3%)       117 (17.3%)         ART regimen at resistance genotyping       5       5		
Other*         137 (18·3%)         117 (17·3%)           ART regimen at resistance genotyping         Image: Comparison of the second se		
ART regimen at resistance genotyping		
Combination therapy with $\geq$ 3 ARVs 597 (79.6%) 531 (78.4%)		
Dual therapy (DTG & Lamivudine) 27(3.6%) 103 (15.2%)		
Dual therapy (DTG & other) 107 (14-3%) 25 (3-7%)		
Mono therapy 19 (2.5%) 18 (2.7%)		
<b>ART duration at DTG initiation</b> (years) 8.7 [2.1 – 17] 9.3 [3.8 – 17]		
Missing 7 (0.9%) 7 (1.0%)		
Year of DTG initiation         2016 [2015 - 2017]         2016 [2015 - 2017]		
Year of genotypic resistance test         2018 [2017 - 2019]         2018 [2017 - 2019]		
Availability of additional (prior) GRTs		
Yes 429 (57·2%) 389 (57·5%)		
No 321 (42·8%) 288 (42·5%)		
<b>Duration on DTG-based ART</b> (years) 1.6 [0.61 – 3.0] 1.7 [0.71 - 3.1]		
Exposure to first generation INSTI		
Yes 193 (25·7%) 251 (37·1%)		
No 484 (64·5%) 426 (62·9%)		
<b>CD4 count at GRT</b> 465 [237 - 718] 483 [250 - 738]		
Missing 193 (25·7%) 165 (24·4%)		
Viral load AUC (of log10 cp/ml during		
DTG based ART) 2·9 [1·6 - 4·6] 2·9 [1·7 – 4·6]		
Missing 25 (3·3%) 0 (0%)		
<b>No. of HIV virus load tests per year</b> $2.7 [2.0 - 4.0]$ $3.0 [2.0 - 4.0]$		
Missing 20 (2·7%) 0 (0%)		
Cohort		
SHCS 118 (15·7%) 109 (16·1%)		
AfA 9 (1.2%) 9 (1.3%)		
SAC 92 (12·3%) 87 (12·9%)		
Aquitaine 215 (28·7%) 195 (28·8%)		
ATHENA 66 (8.8%) 64 (9.5%)		

CBC	89 (11 <sup>.</sup> 9%)	76 (11·2%)
ICONA	8 (1·1%)	5 (0.7%)
UK CHIC/UKHDRD	153 (20·4%)	132 (19·5%)

346 Numbers (%) and medians [interquartile range] are shown.

\* Other subtypes are comprised as follows: For the analysis of resistance conferring mutations - Unknown, N=69 (9.2%); F,

 348
 N=21 (2·8%); AG, N=12 (1·6%); AE, N=11 (1·5%); D, N=11 (1·5%); 06\_CPX, N=7 (0·9%); 18\_CPX, N=2 (0·3%); 11\_CPX, N=1

 349
 (0·1%); 45\_CPX, N=1 (0·1%); AD, N=1 (0·1%); and H, N=1 (0·1%). For the analysis of risk factors for DTG resistance 

 350
 Unknown, N=60 (8·9%); F, N=16 (2·4%); AG, N=11 (1·6%); D, N=10 (1·5%); AE, N=8 (1·2%); 06\_CPX, N=6 (0·9%); 18\_CPX,

 $351 \qquad N=2 \ (0\cdot 3\%); \ 11\_CPX, \ N=1 \ (0\cdot 1\%); \ 45\_CPX, \ N=1 \ (0\cdot 1\%); \ AD, \ N=1 \ (0\cdot 1\%); \ and \ H, \ N=1 \ (0\cdot 1\%).$ 

352 Abbreviations: ATHENA, the AIDS Therapy Evaluation in the Netherlands cohort; Aquitaine, Agence Nationale de la

Recherche sur le SIDA et les hépatites virales (ANRS) CO3 Aquitaine Cohort; ICONA, Italian Cohort of Antiretroviral-Naïve

Patients; CBC, Cologne/Bonn Cohort, Germany; SHCS, Swiss HIV Cohort Study; SAC, South Alberta Clinic Cohort, Canada;

355AfA, Aid for AIDS, South Africa; UK CHIC/UKHDRD, UK Collaborative HIV Cohort (UK CHIC) Study/ UK HIV Drug Resistance356Database.



357

Figure 1: Prevalence of DTG resistance and INSTI DRMs. Genotypic resistance tests of 750 people
with genotypic resistance testing on DTG-based ART were analysed using the Stanford resistance
algorithm to determine INSTI DRMs and resistance level to DTG. Both major and accessory INSTI
DRMs were considered for the number of INSTI DRMs. People with no INSTI DRMs (N = 650, 86.7%),
and who are susceptible to DTG (N = 713, 95.1%) are not displayed.





Figure 2: INSTI drug resistance mutations found in 750 people experiencing virologic failure on a
 DTG-based regimen. Drug resistance mutations were classified as major and accessory according to
 the Stanford resistance database<sup>27</sup>. Bars are coloured by previous history of first generation INSTIS
 (raltegravir, elvitegravir).



368

**Figure 3: Rate ratio for the number of INSTI DRMs**. A negative binomial generalised linear model was fit to the number of major and accessory INSTI DRMs in 750 people with

371 virological failure on DTG-based ART. The plot shows uni- and multivariable point estimates

and 95% confidence intervals of rate ratios.

## 373 Table 2: Resistance levels to DTG, non-nucleoside reverse transcriptase inhibitors and nucleotide

374 reverse transcriptase inhibitors. The number and percentage of people with corresponding drug

375 resistance levels are given for the entire study population. NRTI resistance level is based on median

376 resistance score to ABC, AZT, XTC and TDF/TAF. NNRTI resistance level is based on median resistance

377 score to EFV, ETR, NVP, and RPV.

	DTG resistance level		
	Susceptible & Potential Low	Low, Intermediate, High	
	(N=721)	(N=29)	
NRTI resistance level			
Susceptible	574 (79·6%)	13 (44.8%)	
Potential Low	14 (1.9%)	2 (6·9%)	
Low	14 (1.9%)	1 (3·4%)	
Intermediate	13 (1.8%)	2 (6·9%)	
High	39 (5·4%)	4 (13.8%)	
RT not covered in GRT	67 (9·3%)	7 (24·1%)	
NNRTI resistance level			
Susceptible	543 (75·3%)	11 (37.9%)	
Potential Low	27 (3·7%)	0 (0%)	
Low	21 (2.9%)	0 (0%)	
Intermediate	39 (5·4%)	4 (13.8%)	
High	24 (3·3%)	7 (24·1%)	
RT not covered in GRT	67 (9·3%)	7 (24·1%)	

378

Reference	Comparison		OR [95% CI]
Sex (male)	Female		0.62 [0.28-1.40] 0.38 [0.14-1.06]
Age at DTG initiation (per 10 years	)	+	1.00 [0.75-1.33] 1.03 [0.73-1.44]
HIV Subtype (B)	Non-B		1.25 [0.63-2.49] 1.82 [0.78-4.26]
ART regimen (>=3 drugs)	Dualtherapy (other)		0.82 [0.24-2.81] 0.95 [0.24-3.72]
	Dualtherapy (Lamivudine)		4.92 [1.55-15.63] 6.59 [1.70-25.55]
	Monotherapy		22.45 [8.56-58.91] 37.25 [11.17-124.2]
First gen. INSTIs (No)	Yes		1.41 [0.70-2.87] 1.43 [0.65-3.14]
Duration on DTG (years)		-	0.88 [0.70-1.11] 0.96 [0.75-1.24]
Viral load (log10 AUC)		-	1.39 [0.89-2.18] 1.42 [0.92-2.19]
No. of VL tests (per year)		-	1.13 [0.97-1.32] 1.08 [0.90-1.30]
NRTI resistance (Susceptible)	Potential Low & Low		5.97 [1.78-19.97] 4.62 [1.24-17.2]
	Intermediate & High		6.37 [2.30-17.62] 7.01 [2.52-19.48]
	RT not sequenced		4.48 [1.76-11.39] 1.47 [0.47-4.65]
		Odds Ratio	
		Univariable Multivariable	1

379

380 Figure 4: Odds ratios for DTG resistance levels with 95% confidence intervals from uni- and 381 multivariable ordinal logistic models for genotypic DTG resistance. Cohorts were included as 382 random effect. DTG resistance levels in people with virological failure on DTG-based ART were 383 assessed using the Stanford resistance algorithm.

# 384 Authors' contributions

Conceptualisation (HFG, JACS, RL, ME, RK), Data curation (TL, SH, SI, HO), Methodology (TL, CS, RK
ME, JACS), Formal analysis & Validation (TL, RK), Investigation (TL, SH, SI), Project administration (SH,
SI), Resources (HO, KK, JM, AvS, MS, AAM, JG, CS, GM), Software (TL, KK), Supervision (HFG, JACS, RL,
ME, RK), Visualisation (TL), Writing – original draft (TL, RL, ME, RK), Writing – review & editing (All
authors).

TL and RK have directly accessed and verified the underlying data reported in the manuscript. RL, ME
 and RK contributed equally.

## 392 **Declaration of interests**

393 SMI reports grant funding from NIH NIAAA for the work of ART-CC (payment to institution). AvS 394 reports funding from the Dutch Ministry of Health, Welfare and Sport for the maintenance of the 395 ATHENA database, and grant funding from the European Centre for Disease Prevention and Control 396 (ECDC) (payment to institution). MJG reports honoraria as Ad Hoc member of HIV National Advisory 397 Board from Merck, Gilead Sciences, and ViiV, and a leadership position as Medical Director S Alberta 398 HIV clinic. CAS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for 399 membership of Data Safety and Monitoring Committees, Advisory Committees and for preparation 400 of educational material. HFG has received personal fees from Merck, Gilead Sciences, ViiV, GSK, 401 Janssen, Johnson and Johnson and Novartis, as an advisor/consultant or for DSMB membership and 402 has received a travel grant from Gilead. JACS reports funding for research in this publication from 403 NIH NIAAA (payment to institution), UK NIHR (payment to institution), and the University of Bern 404 (payment to institution). RL reports support for research in this publication by the National Institute 405 of Allergy & Infectious Diseases of the National Institutes of Health under award number 406 R01AI152772, and support from the National Institute of Allergy & Infectious Diseases of the 407 National Institutes of Health under award number R01AI167699 for a separate project pertaining to 408 HIV treatment strategies. ME reports funding for research in this publication from the Swiss National 409 Science Foundation (32FP30-18949) and the National Institutes of Health (Cooperative Agreement 410 AI069924 and R01 AI152772-01). RK reports funding for research in this publication from the Swiss 411 National Science Foundation and the National Institute of Allergy & Infectious Diseases of the 412 National Institutes of Health, and reports grant funding from Gilead Sciences. All other authors 413 declare no competing interest.

# 414 Acknowledgements

415 We would like to acknowledge Anthony Hauser, Suraj Balakrishna, and Marius Zeeb for helpful 416 discussions on data analysis. This study was supported by the National Institute Of Allergy And 417 Infectious Diseases of the National Institutes of Health under Award Number R01Al152772 and the 418 Swiss National Science Foundation (32FP30\_207285, 324730\_207957). The participating cohorts or 419 cohort collaborations were funded by the Swiss National Science Foundation (33CS30 201369) and 420 the Yvonne Jacob Foundation (for the SHCS), the UK Medical Research Council (grant numbers 421 G0000199, G0600337, G0900274, and M004236/1; for the UK Collaborative HIV Cohort), the 422 National Agency for AIDS Research (France REcherche Nord&Sud Sida-hiv Hépatites), the French 423 Agency for Research on AIDS and Viral Hepatitis Demerging Infectious Diseases (ANRSDMIE) and the 424 CHU de Bordeaux (for the ANRS CO3 Aguitaine-AguiVIH-NA cohort), the Dutch Ministry of Health 425 (for the ATHENA cohort), the German Center for Infection Research (8018704707) (for the CBC), 426 ICONA Foundation is supported by unrestricted grants from BMS, Gilead Sciences, Janssen, MSD and 427 ViiV Healthcare. AFA is supported via IeDEA-SA by the U.S. National Institutes of Health's National 428 Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child 429 Health and Human Development, Division of Cancer Epidemiology and Genetics, National Cancer 430 Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National 431 Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the 432 National Institute of Diabetes and Digestive and Kidney Diseases and the Fogarty International 433 Center under Award Number U01Al069924. The ART-CC is funded by the US National Institute on 434 Alcohol Abuse and Alcoholism (U01-AA026209). The content is solely the responsibility of the 435 authors and does not necessarily represent the official views of the National Institutes of Health.

## 436 Data sharing statement

Data underlying the figures and tables reported in this article may be shared following publication of this article. Researchers may submit a methodologically sound proposal for the use of these data to the corresponding author. De-identified data of individual study participants cannot be made available as they are subject to the respective observational HIV cohorts.

## 441 **References**

- WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva,
   Switzerland:World Health Organization; WHO. 2019. p. 3.
- 444 2. The Lancet HIV. End resistance to dolutegravir roll-out. Lancet HIV. 2020 Sep 1;7(9):e593.
- 445 3. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to 446 resistance for dolutegravir. AIDS Rev. 2015;17(1):56–64.
- 447 4. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-448 interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet.

## 449 2013;52(11):981–94.

- 450 5. Cevik M, Orkin C, Sax PE. Emergent resistance to dolutegravir among instinaive patients on
  451 first-line or second-line antiretroviral therapy: A review of published cases. Open Forum
  452 Infect Dis. 2020;7(6).
- 453 6. Pena MJ, Chueca N, D'Avolio A, Zarzalejos JM, Garcia F. Virological failure in HIV to triple
  454 therapy with dolutegravir-based firstline treatment: Rare but possible. Open Forum Infect
  455 Dis. 2019;6(1).
- 456 7. Scherrer AU, Yang W-L, Kouyos RD, Böni J, Yerly S, Klimkait T, et al. Successful Prevention of
  457 Transmission of Integrase Resistance in the Swiss HIV Cohort Study. J Infect Dis.
  458 2016;214(3):399–402.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al.
 Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults
 with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study.
 Lancet. 2013;382(9893):700–8.

- 463 9. Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance
  464 with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31(10):1425–34.
- Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety
  of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or
  tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a
  prospective, multicentre, open-label, factorial, randomised, no. Lancet HIV. 2022;1–13.
- 469 11. Han Y-S, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance
  470 against integrase inhibitors. Infect Genet Evol. 2016;46:286–91.
- 471 12. Brenner BG, Thomas R, Blanco JL, Ibanescu R-I, Oliveira M, Mesplède T, et al. Development of
  472 a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading
  473 to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016;71(7):1948–53.
- 474 13. Arimide DA, Szojka ZI, Zealiyas K, Gebreegziabxier A, Adugna F, Sasinovich S, et al. Pre475 Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C
  476 Infected Patients in Ethiopia. Viruses. 2022;14(4).
- 477 14. Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, et al. Dolutegravir versus
  478 placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated
  479 substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther.
  480 2015;20(3):343-8.
- 481 15. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in
  482 antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24483 week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–62.
- Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the
  rise of HIV drug resistance in low-income and middle-income countries: the role of
  dolutegravir-containing regimens. Lancet Infect Dis. 2019;19(7):e246–52.
- 487 17. Boender TS, Smit C, Van Sighem A, Bezemer D, Ester CJ, Zaheri S, et al. AIDS Therapy
  488 Evaluation in the Netherlands (ATHENA) national observational HIV cohort: Cohort profile.
  489 BMJ Open. 2018;8(9).
- 49018.Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, et al. Severe morbidity491according to sex in the era of combined antiretroviral therapy: The ANRS CO3 aquitaine

## 492 cohort. PLoS One. 2014;9(7).

- Lepri AC, Phillips AN, Monforte A d'A., Castelli F, Antinori A, De Luca A, et al. When to start
  highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the
  ICONA study. AIDS. 2001;15(8):983–90.
- 49620.Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, et al. Causes of death497in HIV-infected patients from the Cologne-Bonn cohort. Infection. 2014;42(1):135–40.
- Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, et al. The creation of a large
  UK-based multicentre cohort of HIV-infected individuals: The UK collaborative HIV cohort (UK
  CHIC) study. HIV Med. 2004;5(2):115–24.
- 501 22. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, et al. Cohort Profile 502 Update: The Swiss HIV Cohort Study (SHCS). Int J Epidemiol. 2022;51(1):33-34J.
- 503 23. Beck PL, Gill MJ, Blahey WB, Sutherland LR. HIV-related non-Hodgkin's lymphoma in Calgary.
  504 Can J Infect Dis. 1996;7(2):115–20.
- 505 24. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill
  506 adherence compared with CD4 count changes for monitoring HIV-infected adults on
  507 antiretroviral therapy. PLoS Med. 2008;5(5):0777–88.
- 50825.May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile:509Antiretroviral therapy cohort collaboration (ART-CC). Int J Epidemiol. 2014;43(3):691–702.
- 510 26. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International
  511 epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ
  512 Open. 2020;10(5).
- 51327.Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin514Infect Dis. 2006;42(11):1608–18.
- 51528.Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: Adaptive context-based516modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18).
- Pineda-Peña A-C, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated
  subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance
  evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337–
  48.
- 52130.Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, et al. Lack of impact of pre-522existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and523treatment outcome. PLoS One. 2017;12(2).
- S24 31. Rolle C-P, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir
  functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective
  study of treatment-experienced, patients living with HIV. AIDS Res Ther. 2021;18(1).
- S27 32. Naeger LK, Harrington P, Komatsu T, Deming D. Effect of dolutegravir functional
   monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant
   patients. Antivir Ther. 2016;21(6):481–8.
- 53033.Von Wyl V, Yerly S, Böni J, Bü rgisser P, Klimkait T, Battegay M, et al. Emergence of HIV-1 drug531resistance in previously untreated patients initiating combination antiretroviral treatment: A532comparison of different regimen types. Arch Intern Med. 2007;167(16):1782–90.
- 533 34. WHO. Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving

- 534 dolutegravir- containing antiretroviral therapy. Geneva; 2022.
- Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated
  tuberculosis in high-burden settings: implementation challenges and research gaps. Lancet
  HIV. 2022;9(2):e130-8.
- Malet I, Delelis O, Nguyen T, Leducq V, Abdi B, Morand-Joubert L, et al. Variability of the HIVpolypurine tract (32PPT) region and implication in integrase inhibitor resistance. J
  Antimicrob Chemother. 2019;74(12):3440–4.
- 54137.Dekker JG, Klaver B, Berkhout B, Das AT. Mutations in the HIV-1 3-Polypurine Tract Can542Confer Dolutegravir Resistance. Antimicrob Agents Chemother. 2022;66(1).
- 54338.Hikichi Y, Groebner JL, Wiengand A, Mellors JW, Kearney MF, Freed EO. Mutations outside544integrase lead to high-level resistance to dolutegravir [CROI Abstract 103]. In: Conference on545Retroviruses and Opportunistic Infections CROI 2023 Abstract eBook. 2023.
- Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and
  switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa:
  Collaborative analysis. Lancet HIV. 2015;2(7):e271–8.

549